Navigation Links
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Date:7/6/2008

with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade 4 neuropathy. There was a lower incidence of alopecia in the OPAXIO arm (2 percent versus 5 percent respectively, p = 0.085), as well as fatigue (16 percent versus 25 percent, p= 0.055), asthenia (11 percent versus 16 percent, p = 0.169), and weight loss (7 percent versus 12 percent, p = 0.121).

Details of the Study

The phase III trial, reported by Mary E. R. O'Brien, M.D., F.R.C.P., et al, of the Royal Marsden Hospital and the Kent Cancer Centre in Surrey, UK, was a randomized, multi-center trial. The trial was conducted at 83 centers in ten countries, and randomized on a 1:1 ratio to evaluate the efficacy and safety of this regimen in patients with chemotherapy-nave NSCLC. Patients with advanced stage IIIb/IV NSCLC and PS 2 were treated with OPAXIO on day 1 of a 21-day cycle, while patients receiving gemcitabine were treated on days 1, 8, and 15 of each 28-day cycle. Vinorelbine was administered on days 1, 8, and 15 of each 21-day cycle. Patients received up to six cycles of treatment, and were not treated until significant toxicities were under control (less than or equal to grade 1). The primary objective was effect on survival, and secondary objectives were determining the efficacy and safety of the treatments.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was previously branded as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is rendered inactive, potentially sparing normal tissue's exposure to high levels of the active drug and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules l
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
2. Genzyme and Isis Complete Licensing of Mipomersen
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
10. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
(Date:11/21/2014)... SAN CLEMENTE, Calif. , Nov. 21, 2014 /PRNewswire/ ... Lab Coats and Performance Scrubs carried out a new ... the medical industry,s very first "limited edition" lab ... the first female professors of surgery in the world. ... departure from its unisex predecessors, with a sleek envelope ...
(Date:11/21/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... Award for Vision, Innovation, and Leadership has been awarded to ... award recognizes an individual who has had a significant impact ... for several decades. "I am honored to ... Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When I ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 22, 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... who allegedly developed Type 2 diabetes due to its ... litigation now underway in U.S. District Court, District of ... documents, the litigation will convene its next Status Conference ... directed Lead Counsel for Plaintiffs and Defendants to meet ...
(Date:11/22/2014)... 22, 2014 The Sports Conflict Institute ... Baroff to its team of conflict resolution professionals. Baroff ... coach, and referee. He has over 30 years experience as ... , “I'm very excited to connect with SCI and bring ... interests to a program with a complete sports focus,” says ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... are better when patients are treated in an ambulance by ... German researchers report. The sooner patients get the clot ... outcome after a stroke, the researchers noted. For the best ... hour after stroke symptoms start, the researchers said. "The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... ubiquitous and pedestrian drugs -- aspirin -- may cut the ... has not yet spread beyond the gland, a new study ... 5,000 men with prostate cancer, 2,000 of whom were taking ...
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... chemotherapy to radiation therapy for muscle invasive bladder cancer allows ... their bladders two years after treatment. This compares to 54 ... largest randomized study of its kind presented at the plenary ... the American Society for Radiation Oncology (ASTRO). , "The trial ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... By Serena Gordon HealthDay Reporter , MONDAY, Oct. ... to sleep-starved parents: Most infants will start sleeping through the ... may take a little longer, however, is for the baby,s ... schedule, according to the study. "The most rapid changes ...
... PICK: Pregnancy outcome affected by immune system genes ... Moffett, at the University of Cambridge, United Kingdom, has ... to and provide protection from common disorders of pregnancy, ... A key step in the initiation of a successful ...
Cached Medicine News:Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9
For the quantitative in vitro determination of Lipase in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Ammonia in plasma...
For the quantitative in vitro determination of Potassium in serum or plasma....
Medicine Products: